Cargando…

Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial

Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Jordy P. W., van Lochem, Ellen G., Roovers, Elisabeth A., Drenth, Joost P. H., Wahab, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105321/
https://www.ncbi.nlm.nih.gov/pubmed/35565738
http://dx.doi.org/10.3390/nu14091771
_version_ 1784708011937234944
author Burger, Jordy P. W.
van Lochem, Ellen G.
Roovers, Elisabeth A.
Drenth, Joost P. H.
Wahab, Peter J.
author_facet Burger, Jordy P. W.
van Lochem, Ellen G.
Roovers, Elisabeth A.
Drenth, Joost P. H.
Wahab, Peter J.
author_sort Burger, Jordy P. W.
collection PubMed
description Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled study, including adults with coeliac disease adhering to a strictly gluten-free diet. Patients were administered gluten in test-cycles of ascending doses of 50, 100, 200, and 500 mg alternated with placebo. Urine portions from 2, 5–17 h after the ingestion were collected and analyzed for GIP using the iVYCHECK-GIP-Urine rapid lateral flow test. Patients completed a diary mapping symptoms (nausea, bloating, diarrhea, abdominal pain, and lower level of energy). Results: We enrolled 15 patients and 7 received all 4 cycles with increasing gluten dosing. GIP was detected from urine in 47% of the patients receiving 50 mg gluten and in 86% with 500 mg gluten. We detected GIP in 20–50% of urine samples after placebo. There was no correlation between symptoms, gluten administration and/or GIP in urine. Conclusions: Gluten intake, even with a dose as low as 50 mg, leads to detectable urinary GIP concentrations. There is no correlation of coeliac disease ascribed symptoms with detection of urinary GIP.
format Online
Article
Text
id pubmed-9105321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91053212022-05-14 Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial Burger, Jordy P. W. van Lochem, Ellen G. Roovers, Elisabeth A. Drenth, Joost P. H. Wahab, Peter J. Nutrients Article Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled study, including adults with coeliac disease adhering to a strictly gluten-free diet. Patients were administered gluten in test-cycles of ascending doses of 50, 100, 200, and 500 mg alternated with placebo. Urine portions from 2, 5–17 h after the ingestion were collected and analyzed for GIP using the iVYCHECK-GIP-Urine rapid lateral flow test. Patients completed a diary mapping symptoms (nausea, bloating, diarrhea, abdominal pain, and lower level of energy). Results: We enrolled 15 patients and 7 received all 4 cycles with increasing gluten dosing. GIP was detected from urine in 47% of the patients receiving 50 mg gluten and in 86% with 500 mg gluten. We detected GIP in 20–50% of urine samples after placebo. There was no correlation between symptoms, gluten administration and/or GIP in urine. Conclusions: Gluten intake, even with a dose as low as 50 mg, leads to detectable urinary GIP concentrations. There is no correlation of coeliac disease ascribed symptoms with detection of urinary GIP. MDPI 2022-04-23 /pmc/articles/PMC9105321/ /pubmed/35565738 http://dx.doi.org/10.3390/nu14091771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Burger, Jordy P. W.
van Lochem, Ellen G.
Roovers, Elisabeth A.
Drenth, Joost P. H.
Wahab, Peter J.
Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
title Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
title_full Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
title_fullStr Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
title_full_unstemmed Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
title_short Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
title_sort dose-escalating (50–500 mg) gluten administration leads to detectable gluten-immunogenic-peptides in urine of patients with coeliac disease which is unrelated to symptoms, a placebo controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105321/
https://www.ncbi.nlm.nih.gov/pubmed/35565738
http://dx.doi.org/10.3390/nu14091771
work_keys_str_mv AT burgerjordypw doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial
AT vanlochemelleng doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial
AT rooverselisabetha doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial
AT drenthjoostph doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial
AT wahabpeterj doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial